According to a ministerial announcement number 1435/2560 published in the Royal Gazette on Tuesday, studies had found that Phenylbutazone could cause aplastic anaemia and agranulocytosis, which could be fatal to people.
The Public Health Ministry exercised the authority bestowed by the Section 86 of the still-in-effect Drug Act 1967 and its revised version in 1987 in issuing the cancellation of 70 Phenylbutazone-laced medicine brands as stated in the announcement's annexe.
Those who disagree with the cancellation could appeal with the Administrative Court in 90 days after the announcement was issued on September 29.
Those brands mentioned in the annexe include Butazone by SSP Laboratories, Chanetazone by Patanakarn Development Pharmacy, Leophen by Charoenbhesaj Lab and Phenylbutazone tablets by HK Pharmaceutical.
Published : November 15, 2017
By : The Nation